Secondly, in terms of clinical applications, LSD1/KDM1A is aberrantly overexpressed in several cancer types, with different LSD1 inhibitors currently developed to treat solid tumors and hematological malignancies [63,64,65]. This evidence concerns the gene KDM1A and cancer.